Data as of Mar 14
| +0.0049 / +0.55%|
Affymax, Inc. is a biopharmaceutical company that is discovering, developing and delivering innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses. It has developed OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. The company is building a pipeline of novel peptide drugs against clinically validated targets that will provide product profiles over therapeutic proteins. Affymax was founded on July 20, 2001 and is headquartered in Palo Alto, CA.
|Richard M. Brenner||Chief Executive Officer & Director|
|J. Weston Rose||President|
|Mark G. Thompson||Chief Financial Officer|
|Anne-Marie Duliege||Chief Medical Officer|
|Andrew T. Blair||Vice President-Medical Affairs|